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Introduction
Among the classic myeloproliferative neoplasia (MPN), 
chronic myeloid leukemia (CML) is characterized by 
a pathognomonic Philadelphia (Ph)-chromosome, 
corresponding to translocation t(9;22) and resulting in the 
BCR-ABL1 oncogene. The classical studies of Fialkow 
et al., based on the analysis of X-linked glucose 6-phosphate 
dehydrogenase (G6PDH) polymorphisms in hemopoietic 
cells of CML female patients carrying a GDPDH 
heterozygosity (1), have shown that the Ph-chromosome 
arises in a multipotent stem cell and can be observed in all 
hemopoietic lineages, including B lymphocytes. This finding 
has been confirmed in further studies, using high sensitivity 
techniques such as fluorescent-in situ hybridization on 
sorted cells (2,3). The possibility of a multistep pathogenesis 
for CML was suggested by the demonstration of an identical 
G6PDH pattern and multiple chromosomal aberrations 
in Ph-negative B-lymphoid cell lines derived from CML 
patients. This observation implies that at least two steps are 
required to develop CML phenotype, one causing abnormal 
proliferation at pluripotent stem cell level, and one inducing 
Ph chromosome in the descendants of these progenitors (4). 
On this basis, the so called “Fialkow hypothesis” suggested 
that a clonal hemopoiesis with genetic instability may evolve 
into CML by acquisition of the Ph-chromosome.
Similar to CML, Ph-negative MPN also arise in a 
multipotent hemopoietic stem cell (5). In 2005, the 
discovery that Janus kinase 2 (JAK2) gene is involved in 
polycythemia vera (PV), essential thrombocythemia (ET) 
and primary myelofibrosis (PMF) has refined current 
diagnostic criteria of MPN (6). In 2013, calreticulin (CALR) 
gene was discovered to be involved in JAK2 negative 
myeloproliferative disorders (7,8) and the mutation of these 
two genes, together with mutations of thrombopoietin 
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receptor gene [myeloproliferative leukemia (MPL)] (9), 
were found to be mutually exclusive (10,11). 
The 2016 revision of the WHO myeloid neoplasm 
classification takes into account the discovery of these 
novel molecular findings, but it does not address the 
classification of MPN cases that present more than one 
genetic abnormality. However, in clinical practice the 
coexistence of different abnormalities has been previously 
described: in particular, the association of JAK2 positive 
MPN and Ph-positive CML is considered rare, but more 
than 25 cases were reported in literature (12). Sporadic, 
rare cases of coexistence of CALR-mutated MPN and Ph-
positive CML have been recently described too. Bonzheim 
et al. reported one case of BCR-ABL1 translocation arising 
in a patient with previous diagnosis of thrombocytosis, 
identified as CALR-mutated ET (13); it was hypothesized 
in a similar case by Cabagnols et al. that a common clone 
harbored both genetic alterations, CALR mutation being 
pre-acquired and BCR-ABL1 translocation being a 
secondary event (14). Two other cases of co-existence of 
chronic phase CML and CALR mutation were described, 
with a CALR-positive PMF diagnosed 7 to 24 months 
after the start of tyrosine kinase inhibitors (TKI) therapy 
for CML; bone marrow (BM) examination revealed 
moderate fibrosis in one case, and prominent collagen 
fibrosis in the other case (15,16). In a recent case by 
Seghatoleslami, del52CALR mutation with a high allele 
burden was found to be present at diagnosis of a blast 
phase CML, associated with the uncommon p190 Bcr-
Abl1 transcript positivity (17).
Here we report a case of coexistence of BCR-ABL1 
fusion gene and CALR mutation, diagnosed due to 
persistent thrombocytosis while the patient was in 
treatment-free, complete molecular remission (CMR) from 
CML.
Case presentation
A 61-year-old woman was diagnosed with Ph+ CML, 
low Sokal risk, in May 2001. She was initially treated 
with hydroxyurea until August, when she was enrolled 
in a GIMEMA protocol (CML 011) (18): she was then 
administered imatinib 400 mg per day in association with 
PEG-interferon (IFN) 50 mcg/week front line, which 
was stopped for skin toxicity after 4 months. She achieved 
complete cytogenetic remission (CCyR) and CMR, defined 
as undetectable Bcr-Abl1 transcript at qualitative real time 
PCR (RT-PCR), within 9 months of treatment, in May 
2002. CMR was stable for 41 months and imatinib was 
discontinued in October 2010 due to gastric intolerance. 
The patient stayed off treatment in confirmed CMR, 
with undetectable Bcr-Abl1 transcript on both BM and 
peripheral blood (PB), in multiple serial samples, for 28 
months. 
In February 2008, a RT quantitative PCR (RT-qPCR) 
analysis on PB disclosed a Bcr-Abl1 /Abl1 ratio of 0.0208%, 
consistent with a MMR.
To determine the depth of Bcr-Abl1 positivity reached 
we also performed Replicate RT-qPCR, a novel, high-
sensitivity PCR. The assay was carried out using custom-
plates provided by Life Technologies, designed to include: 
82 wells for Bcr-Abl1 detection and quantification, 2 wells 
for Abl1 (used as control gene), 2 wells for no template 
control for Bcr-Abl1, 2 wells for no template control for 
Abl1, 4 wells for the unique plasmid DNA to obtain the 
standard curve for Bcr-Abl1, 4 wells for the unique plasmid 
DNA to obtain the standard curve for Abl1 (19,20). Nine 
μg of total RNA of each sample were retro-transcribed 
according to the EAC protocol. Each well of the plate 
contained a cDNA amount corresponding to 100 ng of 
the initial RNA. Final results were expressed as qualitative 
(percentage of positive wells/82 wells) and quantitative 
(mean Bcr-Abl1 copies/mean Abl1 copies %) values, 
reaching a sensitivity equal to MR5.5/MR 6. Replicate-
PCR was also performed on 14 healthy controls to establish 
a positivity threshold for the test, obtained as mean +2 
standard deviation of the number of positive wells in the 
controls (2.7/82 wells).
Thanks to this high sensitivity, test results showed that 
Bcr-Abl1 was detectable before a positive analysis with 
standard method was observed.
The patient refused to start imatinib again, and 
control samples performed every 3 to 6 months thereafter 
maintained very low Bcr-Abl1 levels, ranging between 0% 
and 0.022%, without ever losing CCyR or major molecular 
remission (MMR). In March 2010, she was enrolled in a 
peptide vaccination protocol (CML VAX) (21), that she 
continued for a total of 17 doses until April 2014, showing 
no side effects; in this phase, molecular monitoring showed 
negativity of Bcr-Abl1 transcript since November 2011 
(after 10 doses of vaccine). After starting the CML VAX 
protocol the number of positive wells decreased. The 
patient remained in CMR, with undetectable transcript 
until the latest follow-up, performed in October 2016, 
181 months since the initial diagnosis and almost 12 years 
since the discontinuation of TKI therapy, marking one 
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of the longest treatment-free remissions (TFR) from 
CML obtained so far (22,23). It is conceivable that in this 
particular case, in addition to the effect of TKI, a major role 
was exerted by immunologic response, enhanced by CML 
VAX (24). 
Due to a rising platelet count in subsequent follow-
up blood drawn (maximum reached was 616,000/mm3) 
while CML was well controlled, in order to exclude the 
coexistence of CML and a Ph-negative myeloproliferative 
syndrome, in February 2015, we performed a panel of 
myeloproliferative molecular mutations on a BM aspiration 
sample: the patient had no JAK2 V617F mutation, but 
CALR mutation was present, allelic burden being 46.8%. A 
52 bp deletion in exon 9 of CALR (type1 CALR mutation) 
was in fact identified using capillary fragment analysis and 
the CALR mutation was confirmed using bi-directional 
DNA sequencing. Biopsy showed a myeloproliferative BM 
that was interpreted as ET or possibly PMF at a pre-fibrotic 
stage. At that time, she was off therapy for CML, steadily in 
CMR.
We then retrospectively repeated CALR quantitative 
analysis on previous blood samples, to determine when the 
CALR clone had emerged. We found that CALR mutation 
had been present (10.5%) since the moment of the CML 
diagnosis, in 2001; its levels, as well as platelet count, slowly 
increased through time, while the patient first gained CCyR 
from CML, 9 months after the initial diagnosis, and BCR-
ABL1 transcript decreased until undetectability in May 
2006 (Table 1).
Discussion
Our patient retrospectively presented a CALR mutation 
since the initial diagnosis of CML, but CALR allelic 
burden rose and became phenotypically relevant, producing 
thrombocytosis, after CMR from CML and when TKI-
independence was obtained. Therefore, it is possible that in 
this particular case, unlike in the case previously described 
by Cabagnos et al., two independent clones had carried 
the two molecular alterations: BCR-ABL1-positive clone 
Table 1 BCR-ABL1 and CALR molecular analysis at diagnosis and during follow-up 
Timepoint Therapy Cytogenetics Bcr-Abl RT-QPCR Calreticulin level (%) Plts/mm3 Replicate PCR (pos wells/total wells)
Diagnosis None 20/20 Ph+ Positive 10.54 346,000
3 months Ima + PEG-IFN 4/10 Ph+ Positive 16.08 160,000
6 months Ima 1/20 Ph+ Positive NA 257,000
9 months Ima 0/20 Ph+ Negative 28.54 314,000
12 months Ima 0/20 Ph+ Negative 17.53 310,000
18 months Ima NA Negative 17.17 315,000
24 months Ima 0/20 Ph+ Negative 25.57 313,000
48 months Stop Ima 0/15 Ph+ Negative NA 336,000
55 months None NA 0% 33.22 292,000
64 months None NA 0% 38.22 427,000 7/82
72 months None 0/20 Ph+ 0% NA 371,000 10/82
83 months None 0/20 Ph+ 0.0176% 41.69 453,000
88 months Vaccine NA 0.022% 41.67 364,000 68/82
124 months None NA 0% MR4.0 43.5 459,000
134 months None NA 0% MR4.5 NA 452,000 1/82
160 months None NA 0% MR4.5 50.19 542,000
165 months None NA 0% MR4.5 46.8 616,000
Cytogenetic analysis, molecular analysis of BCR-ABL1, calreticulin levels (when available) and platelet counts at different time points, 
from initial diagnosis to subsequent follow-up. Replicate-PCR results (expressed as positive wells/total wells) are also shown, to clarify the 
depth of molecular response.
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was dominant at the beginning, but responded rapidly to 
TKI therapy and soon became undetectable. Meanwhile, 
CALR-positive clone could have gained selective advantage 
from the inhibition of the Ph-positive clone exerted first 
by imatinib, later by CML VAX immunotherapy, and 
consequently started to grow, producing thrombocytosis 
that prompted a screening for Ph-negative diseases. 
As stated by Fialkow in 1981 for CML, chronic MPN 
probably arise via a multistep pathogenesis, including 
an early step in hematopoietic stem cells (HSC), able to 
determine the initial clonal proliferation and a following 
subclonal evolution because of chromosomal instability (4). 
Thus, it is also possible that in our case an earlier event 
occurred in HSC, leading to the subsequent development of 
two different mutated subclones, respectively BCR-ABL1-
positive and CALR-positive. 
As both CML and Ph-negative MPN are disorders of the 
HSCs, the coexistence in a number of patients of multiple 
genetic lesions, partially sensitive to TKIs treatment, may 
be a clue to evaluate the clonal evolution of the leukemic 
stem cell population.
Conclusions
We reported the case of a CML patient that reached 
CMR and maintained TKI TFR for almost 12 years, 
associated with a CALR-mutated ET; the association 
of Ph-positive CML in persistent CMR and of CALR-
positive ET has not been described before. However, 
few other cases reporting the coexistence of BCR-ABL1 
and other Ph-negative MPN markers (CALR or JAK2 
mutations) have been described: in these cases, the pattern 
of clonal evolution, that is, the timing of the different 
genetic abnormalities and the “stemness” level of the cell 
involved in the first alteration, was highly heterogeneous. 
Investigating the coexistence of BCR-ABL1 and other Ph-
negative MPN markers at different time-points may help 
interpretation of the various clinical and pathogenetic 
features of myeloproliferative diseases. Although current 
guidelines do not recommend to perform a molecular 
screening for CALR mutations when a Ph-positive CML 
has been diagnosed, molecular analysis for JAK2 and 
CALR mutations may be indicated in selected cases.
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